At present, immunotherapy with programmed cell death protein 1 inhibitors is approved for metastatic and locally advanced cSCC and has been employed in a limited number of RDEB patients, providing some clinical benefit [54, 55]. The gene discussed is PDCD1; the disease is recessive dystrophic epidermolysis bullosa.